摘要
目的探讨丙氨酰-谷氨酰胺联合神经节苷脂治疗重症脑卒中(SCA)的临床疗效及对患者免疫、氧化应激指标的影响。方法选取医院2018年12月至2022年11月收治的SCA患者103例,按随机数字表法分为观察组(52例)和对照组(51例)。两组患者均予基础治疗及注射用单唾液酸四己糖神经节苷脂钠静脉注射,观察组患者加用丙氨酰-谷氨酰胺注射液鼻饲。结果与对照组比较,观察组患者治疗后的血清白蛋白、前白蛋白及免疫球蛋白A、免疫球蛋白G、免疫球蛋白M水平均显著升高(P<0.05);基质金属蛋白酶-9、应激诱导蛋白Sestrin 2、硫氧还蛋白、过氧化还原酶1水平均显著降低(P<0.05),美国国立卫生研究院卒中量表评分、改良Rankin量表评分均显著降低,Barthel指数显著升高(P<0.05);两组不良反应发生率无显著差异(P>0.05)。结论丙氨酰-谷氨酰胺联合神经节苷脂治疗SCA,可改善患者的营养状态,增强机体免疫功能,缓解机体氧化应激,降低血清氧化应激相关指标水平,改善患者神经功能及日常生活能力。
Objective To investigate the clinical efficacy of alanyl-glutamine combined with ganglioside in the treatment of severe cerebral apoplexy(SCA)and its effect on the immune and oxidative stress indicators in patients.Methods A total of 103 patients with SCA admitted to the hospital from December 2018 to November 2022 were selected and divided into the observation group(52 cases)and the control group(51 cases)by the random number table method.Both groups were given the basic treatment and intravenous injection of Monosialotetrahexosylganglioside Sodium for Injection,on this basis,the observation group was given the nasal feeding with Alanyl Glutamine Injection.Results Compared with those in the control group,the serum albumin(Alb),prealbumin(PAB),immunoglobulin A(IgA),immunoglobulin G(IgG)and immunoglobulin M(IgM)levels in the observation group were significantly higher after treatment(P<0.05);the matrix metalloproteinase-9(MMP-9),stress-induced protein Sestrin 2,thioredoxin(Trx)and peroxiredoxin 1(PRDX1)levels were significantly lower after treatment(P<0.05);the National Institute of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)scores were significantly lower,and the Barthel index was significantly higher after treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Alanyl-glutamine combined with ganglioside in the treatment of SCA can improve patients′nutritional status,enhance the immune function,alleviate the oxidative stress,reduce the levels of serum oxidative stress-related indicators,and improve the neurological function and daily living ability.
作者
谈剑
张炤杰
李晶晶
敖丹
TAN Jian;ZHANG Zhaojie;LI Jingjing;AO Dan(Lishui District People's Hospital of Nanjing·Lishui Branch of Zhongda Hospital,Southeast University,Nanjing,Jiangsu,China 211200)
出处
《中国药业》
CAS
2023年第24期117-120,共4页
China Pharmaceuticals
基金
江苏省重点研发计划(社会发展)专项资金项目[BA2021616]。
